Compounds > pyrazinoic acid

pyrazinoic acid and isoniazid

pyrazinoic acid has been researched along with isoniazid in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19901 (16.67)18.7374
1990's0 (0.00)18.2507
2000's3 (50.00)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chung, WJ; Jacobs, WR; Ngo, SC; Sayahi, H; Welch, JT; Zimhony, O1
Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL1
Acocella, G; Conti, R; Grassi, C; Luisetti, M; Pozzi, E1
Draper, P1
Wade, MM; Zhang, Y1
Cheng, LW; Chibale, K; Land, KM; Liu, N; Seldon, R; Smith, GS; Smith, PJ; Stringer, T; Tam, C; Warner, DF1

Other Studies

6 other study(ies) available for pyrazinoic acid and isoniazid

ArticleYear
Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:7

    Topics: Bacterial Proteins; Cell-Free System; Fatty Acid Synthases; Humans; Inhibitory Concentration 50; Kinetics; Mass Spectrometry; Molecular Structure; Mycobacterium tuberculosis; NADP; Oxidation-Reduction; Pyrazinamide; Reproducibility of Results; Substrate Specificity

2007
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
    PloS one, 2016, Volume: 11, Issue:10

    Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat

2016
Pharmacokinetic studies on antituberculosis regimens in humans. I. Absorption and metabolism of the compounds used in the initial intensive phase of the short-course regimens: single administration study.
    The American review of respiratory disease, 1985, Volume: 132, Issue:3

    Topics: Absorption; Antitubercular Agents; Humans; Isoniazid; Kinetics; Male; Pyrazinamide; Rifampin; Streptomycin

1985
Lipid biochemistry takes a stand against tuberculosis.
    Nature medicine, 2000, Volume: 6, Issue:9

    Topics: Acetyltransferases; Antitubercular Agents; Bacterial Proteins; Drug Therapy, Combination; Fatty Acid Synthase, Type II; Fatty Acid Synthases; Humans; Isoniazid; Multienzyme Complexes; Prodrugs; Pyrazinamide; Tuberculosis, Pulmonary

2000
Anaerobic incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis.
    Journal of medical microbiology, 2004, Volume: 53, Issue:Pt 8

    Topics: Adenosine Triphosphatases; Anaerobiosis; Antitubercular Agents; Colony Count, Microbial; Electron Transport; Energy Metabolism; Enzyme Inhibitors; Isoniazid; Mycobacterium tuberculosis; Nitrates; Oxygen; Pyrazinamide; Rifampin

2004
Antimicrobial activity of organometallic isonicotinyl and pyrazinyl ferrocenyl-derived complexes.
    Dalton transactions (Cambridge, England : 2003), 2017, Aug-14, Volume: 46, Issue:30

    Topics: Aldehydes; Animals; Anti-Bacterial Agents; Antiparasitic Agents; CHO Cells; Coordination Complexes; Cricetulus; Ferrous Compounds; Humans; Iridium; Isoniazid; Isonicotinic Acids; Metallocenes; Mycobacterium tuberculosis; Plasmodium falciparum; Pyrazinamide; Rhodium; Ruthenium; Trichomonas vaginalis

2017